This is an open label study in 2 cohorts of healthy volunteers and 1 cohort of patients with Schizophrenia, designed to evaluate the Dopamine D2 and D3 Receptor Occupancy by SIPI6398 at various doses and timepoints.
Participant is aged 18-55 years, inclusive.
BMI between 19.0 and 32.0 kg/m2, inclusive.
Participant is medically healthy as determined by clinical evaluations including laboratory safety tests, medical history, physical examination, ECG, and vital sign measurements performed at the Screening visit and before administration of the initial dose of study drug.
Participant is willing and able to be confined to an inpatient setting for the study duration, follow instructions, and comply with the protocol requirements.
Women of childbearing potential (WOCBP), or fertile men whose sexual partners are WOCBP, who are unwilling or unable to use at least 1 highly effective method of contraception during the study and for 90 days following the last dose of trial medication. A female participant is considered to be a WOCBP after menarche and until she is in a postmenopausal state for 12 months or otherwise permanently sterile (for which acceptable methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy).
Females who are pregnant, lactating, or less than 90 days postpartum prior to the Screening Visit.
History or presence of any clinically significant illness, such as cardiovascular, neurologic, pulmonary, hepatic, renal, metabolic, gastrointestinal, urologic, immunologic, endocrine, or psychiatric disease, considered by the investigator.
Risk for suicidal behavior during the study as determined by the investigator's clinical assessment and C-SSRS as confirmed by the following: Answers "Yes" to any of the 5 items (C-SSRS - ideation) within the 3 months before Screening or between the Screening and Baseline Visits, or answers "Yes" to any of the 5 items (C-SSRS behavior) within the 12 months before Screening or between the Screening and Baseline Visits, or has a history of nonsuicidal, self-injurious behavior in the past 12 months.
Sequential
SIPI6398 Tablets
DrugSIPI6398 Tablets will be administered orally once daily for 7 consecutive days to healthy volunteers or for 8 consecutive days to patients with schizophrenia.
Brain dopamine D2 and D3 receptor occupancy following oral doses as measured by PET.
Safety and Tolerability as Measured by Reported Adverse Events
Click on the lead sponsor to view all of their trials.
Shanghai Zhongze Therapeutics Co., Ltd.
Lead sponsor
Yale University
Collaborator
This trial is not recruiting at the moment. You can still explore other options:
